Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: A GINECO group study

Targeted Oncology

Volumn 8, Issue 4, 2013, Pages 243-251

  Trédan, Olivier ^a   Treilleux, Isabelle ^a   Wang, Qing ^a   Gane, Nicolas ^b   Pissaloux, Daniel ^a   Bonnin, Nathalie ^a   Petit, Thierry ^c   Cretin, Jacques ^d   Bonichon Lamichhane, Nathalie ^e   Priou, Frank ^f   Lavau Denes, Sandrine ^g   Mari, Véronique ^h   Freyer, Gilles ⁱ   Lebrun, Daniela ^j   Alexandre, Jérôme ^k   Ray Coquard, Isabelle ^a  

^a CENTRE LÉON BÉRARD   (France)

^b Centre Léon Bérard ^*  (France)

^c CENTRE PAUL STRAUSS   (France)

^d Clinique Bonnefon   (France)

^e Clinique Tivoli   (France)

^f Centre hospitalier Les Oudairies   (France)

^g DUPUYTREN UNIVERSITY HOSPITAL   (France)

^h CENTRE ANTOINE LACASSAGNE   (France)

ⁱ CENTRE HOSPITALIER LYON SUD   (France)

^j INSTITUT JEAN GODINOT   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

Biomarkers; Endometrial carcinoma; Everolimus; Metastatic disease

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE LKB1;

4E BP1 GENE; ADULT; ADVANCED CANCER; AGED; AKT1 GENE; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIUM CARCINOMA; ER GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE DELETION; HUMAN; IMMUNOHISTOCHEMISTRY; LKB1 GENE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE K RAS; ONCOGENE NEU; OVERALL SURVIVAL; P4E BP1 GENE; PAKT GENE; PHASE 2 CLINICAL TRIAL; PI3K GENE; PIK3CA GENE; PR GENE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PTEN GENE; S6RP GENE; SIGNAL TRANSDUCTION; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84890554032     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0242-9     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Dizon DS (2010) Treatment options for advanced endometrial carcinoma. Gynecol Oncol 117:373-381
3. Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94:455-459
4. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH et al (1997) P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 94:9052-9057
5. Bae-Jump VL, Zhou C, Boggess JF, Whang YE, Barroilhet L, Gehrig PA (2010) Rapamycin inhibits cell proliferation in type i and type ii endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecol Oncol 119:579-585
6. Ray-Coquard I, Plantade A, Petit T, Lebrun-Jezekova D, Lavau-Denes S, Cretin J et al (2010) The ENDORAD trial: RAD001 (everolimus) monotherapy as second line or third line treatment of advanced endometrial carcinoma: a phase II trial of GINECO group. Ann Oncol 21 (suppl18). (abstract)
7. Meyer LA, Slomovitz BM, Djordjevic B, Galbincea JM, Johnston TA, Munsell M et al (2011) The search continues: looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. J Clin Oncol 29. (abstract)
8. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:437-481
9. Di NF, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T et al (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120:2858-2866
10. Bansal N, Yendluri V, Wenham RM (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16:8-13
11. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA et al (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92:924-930
12. Colombo N, Mcmeekin S, Schwartz P, Kostka J, Sessa C, Gehrin P et al (2007) A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 25. (abstract)
13. Mackay H, Welch S, Tsao MS, Biagi JJ, Elit L, Ghatage P et al (2011) Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. J Clin Oncol 29. (abstract)
14. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM et al (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials group. J Clin Oncol 29:3278-3285
15. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR et al (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116:5415-5419
16. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R et al (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative rad001 correlates with prolonged inactivation of ribosomal protein s6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261
17. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J et al (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013-1023
18. Gehrig PA, Bae-Jump VL (2010) Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 116:187-194
19. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319
20. Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P et al (2008) PTEN loss does not predict for response to rad001 (everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 14:3993-4001
21. Mori N, Kyo S, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y et al (2007) Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosis. Cancer Sci 98:1881-1888
22. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-RAS mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:814-824
23. Xing D, Orsulic S (2005) Modeling resistance to pathway-targeted therapy in ovarian cancer. Cell Cycle 4:1004-1006